Genmab — December 2016
-
2 advokatfirmaer undersøger Sgens' 15% fald i tirsdags http://www.marketwatch.com/story/shareholder-alert-bronstein-gewirtz-grossman-llc-announces-investigation-of-seattle-genetics-inc-sgen-2016-12-28 http://www.businesswire.com/news/home/20161228005333/en/
-
Ofatumumab Versus Rituximab ORCHARRD http://ascopubs.org/doi/pdf/10.1200/JCO.2016.69.0198
-
"In conclusion, results of this study showed that use of ofatumumab instead of rituximab in conjunction with standard
salvage chemotherapy was not able to overcome treatment resistance in early relapsed or refractory DLBCL. Clearly, for these patients, other treatment approaches are eagerly awaited." -
God morgen. Phase 2, Dara i Soldering MM er lukket: https://clinicaltrials.gov/ct2/show/NCT02316106?term=NCT02316106&rank=1
-
God morgen - og tak Bongo.
-
Ingen problem, bare en del af morgen ritualet. Jeg er meget glad for PI. Vi diskuterede på et tidspunkt finansierings model, er der noget nyt? Mit nytårs forsæt er at sælge en aktie når vi rammer 1600kr. 600kr. til PI og 1000kr til en flaske god whisky. Hvor skal jeg sende pengene?
-
Tak Bob.
-
Jeg skriver om donationsmuligheden i min nytårstale i dag eller morgen.
-
MrTopStep recommendation is based on Zacks research, which I think is sh**, but he has a lot of twitter followers and you can never get enough free advertising
https://mrtopstep.com/4-biotech-stocks-with-bright-prospects-in-2017/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind